Table 4.

Antimicrobial resistance patterns from the main Gram-negative bacteria of neonates with sepsis, 2018–2020

Antibiotics	E. coli n = 44	% (95% CI)	Klebsiella n = 10	% (95% CI)
Piperacillin–tazobactam	2/40	5.0 (1.4–16.5)	3/10	30.0 (10.8–60.3)
Cefotaxime	22/44	50.0 (35.8–64.2)	6/8	75.0 (40.9–92.8)
Ceftriaxone	29/40	72.5 (57.1–83.9)	8/10	80.0 (49.0–94.3)
Ceftazidime	13/40	32.5 (20.1–47.9)	4/10	40.0 (16.8–68.7)
Imipenem	0/39	0 (0–8.9)	1/10	10.0 (1.8–40.4)
Meropenem	0/37	0 (0–9.4)	1/10	10.0 (1.8–40.4)
Ertapenem	0/32	0 (0–10.7)	0/10	0 (0–27.8)
Ampicillin	35/44	79.5 (65.5–88.5)	9/10	90.0 (59.6–98.2)
Aztreonam	15/35	42.9 (27.9–59.1)	3/10	30.0 (10.8–60.3)
Amikacin	4/44	9.1 (3.6–21.2)	0/10	0 (0–27.8)
Gentamicin	15/44	34.1 (21.9–48.9)	4/10	40.0 (16.8–68.7)
Tobramycin	22/44	50.0 (34.6–65.4)	4/8	50.0 (21.5–78.5)
Ciprofloxacin	23/44	52.3 (36.9–67.6)	0/10	0 (0–27.8)
Ofloxacin	17/40	42.5 (26.5–58.5)	0/10	0 (0–27.8)